姜婷婷,仲昭辉,蔡悦萍,张关敏

• 1:北京中医药大学第三附属医院药学部
• 2:北京大学肿瘤医院暨北京市肿瘤防治研究所药剂科
• 3:恶性肿瘤发病机制及转化研究教育部重点实验室
• 4:北京中医药大学东方医院药学部

摘要(Abstract)：

报道临床药师参与1例淋巴瘤化疗患者下肢静脉血栓及抗凝治疗的病例。患者，男，20岁，以“活动性憋气近1月”为主诉收入院，诊断为非霍奇金淋巴瘤，患者在化疗过程中出现下肢静脉血栓，临床药师从血栓发生的高危因素、防治和药学监护等方面展开分析，为患者制定个性化药学服务。经临床药师干预，患者病情稳定，未出现不良反应。

关键词(KeyWords)： 静脉血栓;高危因素;治疗;临床用药

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 姜婷婷,仲昭辉,蔡悦萍,张关敏

DOI: 10.19577/j.1007-4406.2023.05.013

参考文献(References)：

• [1]中国健康促进基金会血栓与血管专项基金专家委员会,中华医学会呼吸病学分会肺栓塞与肺血管病学组,中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会.医院内静脉血栓栓塞症防治与管理建议[J].中华医学杂志, 2018, 98(18):1383.
• [2] HEIT J A, SPENCER F A, WHITE R H. The epidemiology of venous thromboembolism[J]. J Thromb Thrombolysis, 2016,41(1):3.
• [3]中国临床肿瘤学会肿瘤与血栓专家委员会.肿瘤相关静脉血栓栓塞症预防与治疗指南(2019版)[J].中国肿瘤临床, 2019,46(13):653.
• [4] KHORANA A A. Venous thromboembolism and prognosis in cancer[J]. Thromb Res, 2010, 125(6):490.
• [5]刘鹏飞,李亚妮,王华庆.恶性淋巴瘤血栓形成的研究进展[J].中国肿瘤临床, 2014, 41(6):408.
• [6]王南南,陈冠男,余飞,等.肿瘤相关静脉血栓栓塞症预防和治疗的现状与挑战[J].现代肿瘤医学, 2018, 26(2):310.
• [7]杨婧诗,邹立群.淋巴瘤相关静脉血栓的影响因素及风险评估模型的研究进展[J].中国全科医学, 2021, 24(23):2992.
• [8] KEKRE N, CONNORS J M. Venous thromboembolism incidence in hematologic malignancies[J]. Blood Rev, 2019, 33:24.
• [9] YOKOYAMA K. Thrombosis in lymphoma patients and in myeloma patients[J]. Keio J Med, 2015, 64(3):37.
• [10]杨惠芬. PICC预防肿瘤患者化疗所致静脉炎的临床观察[J].河北医学, 2006, 12(12):1285.
• [11] KAHALE L A, TSOLAKIAN I G, HAKOUM M B, et al.Anticoagulation for people with cancer and central venous catheters[J]. Cochrane Database Syst Rev, 2018, 6(6):CD006468.
• [12] ANTIC D, MILIC N, NIKOLOVSKI S, et al. Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients[J]. Am J Hematol, 2016, 91(10):1014.
• [13] ALDOSS I, DAN D E. How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia[J]. Blood, 2020:987.
• [14] JACCARD A, GACHARD N, MARIN B, et al. Efficacy o f L-a s p a r a g i n a s e w i t h m e t h o t r e x a t e a n d d e x a m e t h a s o n e(AspaMetDex regimen)in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study[J]. Blood,2011, 117(6):1834.
• [15] BARCELóR, MU?OZ A, LóPEZ-VIVANCO G. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine[J].Cancer, 2005, 104(5):1110.
• [16] LEE J H, LEE J, YHIM H Y, et al. Venous thromboembolism following L-asparaginase treatment for lymphoid malignancies in Korea[J]. J Thromb Haemost, 2017, 15(4):655.
• [17] KHORANA A A, FRANCIS C W, CULAKOVA E, et al. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study[J]. Cancer, 2005, 104(12):2822.
• [18] STEUER C E, BEHERA M, KIM S, et al. Predictors and outcomes of venous thromboembolism in hospitalized lung cancer patients:a Nationwide Inpatient Sample database analysis[J]. Lung Cancer,2015, 88(1):80.
• [19] BARBAR S, NOVENTA F, ROSSETTO V, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism:the Padua Prediction Score[J]. J Thromb Haemost, 2010, 8(11):2450.
• [20] BARNI S, LABIANCA R, AGNELLI G, et al. Chemotherapyassociated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis:results of a retrospective analysis of the PROTECHT study[J]. J Transl Med, 2011, 9:179.
• [21]艾力江·阿木提,曾巧英,依再提古丽·司马义,等.临床药师对小细胞肺癌合并下肢深静脉血栓患者的药学监护[J].中国医院用药评价与分析, 2018, 18(11):1578.
• [22] STEVENS S M, WOLLER S C, KREUZIGER L B, et al.Antithrombotic therapy for VTE disease[J]. Chest, 2021, 160(6):e545.
• [23] KAHALE L A, MATAR C F, HAKOUM M B, et al. Anticoagulation for the initial treatment of venous thromboembolism in people with cancer[J]. Cochrane Database Syst Rev, 2021, 12(12):CD006649.
• [24] YOUNG A M, MARSHALL A, THIRLWALL J, et al. Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism:results of a randomized trial(SELECT-D)[J]. J Clin Oncol, 2018, 36(20):2017.
• [25] RASKOB G E, VAN ES N, VERHAMME P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism[J].J Vasc Surg Venous Lymphatic Disord, 2019, 7(4):618.
• [26] KHORANA A A, NOBLE S, LEE A Y Y, et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism:guidance from the SSC of the ISTH[J]. J Thromb Haemost, 2018, 16(9):1891.
• [27] ROSS J A, MILLER M M, ROJAS H C M. Comparative effectiveness and safety of direct oral anticoagulants(DOACs)versus conventional anticoagulation for the treatment of cancerrelated venous thromboembolism:a retrospective analysis[J].Thromb Res, 2017, 150:86.
• [28]王瑶,傅麒宁,刘丽萍.利伐沙班在深静脉血栓形成治疗中的应用进展[J].现代医药卫生, 2021, 37(10):1683.
• [29] KREUTZ R, LLAU J, NORRVING B, et al. Management consensus guidance for the use of rivaroxaban-an oral, direct factor Xa inhibitor[J]. Thromb Haemost, 2012, 108(11):876.
• [30]中华医学会外科学分会血管外科学组.利伐沙班临床应用中国专家建议:深静脉血栓形成治疗分册[J].中国血管外科杂志(电子版), 2013, 5(4):209.
• [31]杨艳敏,邵兴慧.新型口服抗凝药在心房颤动抗栓治疗中的应用[J].中国医刊, 2014, 49(1):7.
• [32] K U B I T Z A D, B E C K A M, W E N S I N G G, e t a l. S a f e t y,pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects[J]. Eur J Clin Pharmacol, 2005, 61(12):873.
• [33]中华心血管病杂志血栓循证工作组.非瓣膜病心房颤动患者应用新型口服抗凝药物中国专家建议[J].中华心血管病杂志, 2014,42(5):362.
• [34] NOBLE S, PROUT H, NELSON A. Patients'experiences of LIving with CANcer-associated thrombosis:the PELICAN study[J].Patient Prefer Adherence, 2015, 9:337.